The mutation is also common enough to make it worthwhile to set up a simple diagnostic test that should be offered as part of genetic counseling to all Finnish high-risk breast cancer cases negative for mutations in BRCA1 and BRCA2. The same recommendation would most likely apply also to other high-risk PALB2 founder mutations present in other populations world-wide. Here, BRCA2 is linked to breast carcinoma.